WILMINGTON, Mass., July 2, 2014 /PRNewswire/ -- Implant Sciences
Corporation (OTCQB: IMSC), a high technology supplier of systems
and sensors for homeland security and defense markets, today
announced the Boston Business Journal has included Implant Sciences
in its annual list of the 50 fastest growing publicly traded
companies in Massachusetts. Ranked
by two-year revenue growth as of each company's most recent fiscal
year, Implant Sciences was 23rd in the state, with an
80.65% increase in revenues for the two-year period from
July 1, 2011 to June 30, 2013. For the one-year period between
July 1, 2012 and June 30, 2013, Implant Sciences had a revenue
increase of 252.82%.
"We are proud to be recognized as a top-ranking growth company
in Massachusetts. As a high-tech
manufacturer, we serve both our domestic and international
customers with high-performance made-in-the USA next-generation explosives trace detection
systems. As our business continues to expand, we look forward to
increasing our manufacturing base in Massachusetts by providing high-tech
engineering and manufacturing jobs," stated Implant Sciences CEO
Glenn D. Bolduc.
About Implant Sciences
Implant Sciences is a
leader in developing and manufacturing advanced detection
capabilities to counter and eliminate the ever-evolving threats
from explosives and drugs. The Company's team of dedicated trace
detection experts has developed proprietary technologies used in
its commercial products, thousands of which have been sold across
more than 50 countries worldwide. Implant Sciences is only the
third manufacturer, and the sole American-owned company, to
currently have an ETD system named as a Qualified Product by the US
Transportation Security Administration. The Company's ETDs have
received approvals and certifications from several international
regulatory agencies including the TSA in the U.S., STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution". All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain
certain "forward-looking statements," as that term is defined in
the Private Securities Litigation Reform Act of 1995. Such
statements are based on management's current expectations and are
subject to risks and uncertainties that could cause the Company's
actual results to differ materially from the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, the risks that we will be required to repay all of our
indebtedness to our secured lenders by March
31, 2015; if we are unable to satisfy our obligations and to
raise additional capital to fund operations, our secured lenders
may seize our assets and our business may fail; we continue to
incur substantial operating losses and may never be profitable; our
independent registered public accounting firm has expressed
substantial doubt as to our ability to continue as a going concern;
our explosives detection products and technologies (including any
new products we may develop) may not be accepted by the
Transportation Security Administration or by other U.S. or foreign
government and law enforcement agencies or commercial consumers of
security products; economic, political and other risks associated
with international sales and operations could adversely affect our
sales; liability claims related to our products or our handling of
hazardous materials could damage our reputation and have a material
adverse effect on our financial results; our business is subject to
intense competition; our markets are subject to rapid technology
change and our success will depend on our ability to develop and
introduce new products; we may not be able to retain our management
and key employees or identify, hire and retain additional personnel
as needed; we may not be able to enforce our patent and other
intellectual property rights or operate without infringing on the
proprietary rights of others; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and 8-K.
Such statements are based on management's current expectations and
assumptions which could differ materially from the forward-looking
statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation